Analyst firms · Morgan Stanley · DXCM

Morgan Stanley DXCM price target and rating history

DexCom Inc. (DXCM) · Health Care

Morgan Stanley rates DexCom Inc. (DXCM) Overweight with a $75 price target, as of its latest action on Dec 2, 2025. It has published 5 rating actions on DXCM since October 2021, including 1 upgrade and 0 downgrades. Across 5 firms with a DXCM price target in the last 12 months, the median target is $86. Morgan Stanley's $75 is 13% below that.

Current rating
Overweight
Price target
$75
Median target, all firms
$86
Actions on DXCM
5

Morgan Stanley price target on DXCM

$576$326$7520222023202420252026
Morgan Stanley price target on DXCM, each point a stated target, October 2021 to December 2025.

Every Morgan Stanley rating on DXCM

How other firms rate DXCM

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
BarclaysOverweight$115Oct 7, 2026
Deutsche BankBuy$86Jun 23, 2026
The Benchmark CompanyBuy$77May 12, 2026
Evercore ISIOutperform$90Mar 24, 2026
Morgan StanleyOverweight$75Dec 2, 2025

Questions about Morgan Stanley and DXCM

What is Morgan Stanley's price target for DXCM?
Morgan Stanley's latest stated price target for DexCom Inc. (DXCM) is $75, from its action on Dec 2, 2025.
What is Morgan Stanley's rating on DXCM?
Morgan Stanley rates DXCM Overweight, a bullish rating, as of Dec 2, 2025.
When did Morgan Stanley last change its view on DXCM?
On Dec 2, 2025, Morgan Stanley upgrades to Overweight from Equal-Weight, price target $75.
How does Morgan Stanley's DXCM target compare with other analysts?
Across 5 firms with a DXCM price target in the last 12 months, the median target is $86. Morgan Stanley's $75 is 13% below that.

More DXCM rating histories

All Morgan Stanley ratingsDXCM news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.